Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells

5 views | Jun 12 2022

Zhongbo Du et al. thought that the Notch1 and Notch4 inhibitors GSI-IX and RO4929097 were promising therapeutic agents for the treatment of CRPC. [Read the Full Post]

Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes

45 views | Jun 11 2022

Clara Bonanad et al. it is imperative to deepen our knowledge regarding the management of these challenging patients through real-world data and specifically designed geriatric studies to help resolve the questions remaining in their disease management. [Read the Full Post]

Paracrine production of IL-6 promotes a hypercoagulable state in pancreatic cancer

224 views | Feb 09 2022

Silu Wang et al. found the key role of the Jagged/Notch/IL-6/STAT3 feedback loop in the development of a hypercoagulable state in pancreatic cance. [Read the Full Post]

γ-Secretase inhibitors for breast cancer and hepatocellular carcinoma: From mechanism to treatment

224 views | Feb 09 2022

Hui Jia et al. thought that the γ-secretase complex was very important for activation of the Notch receptor and regulation of target-gene transcription. [Read the Full Post]

DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment

307 views | Jan 06 2022

Mamta Kumari et al. found that DLL4 mAb and GSIs were expected to act synergistically to block the Notch signal mediated BCSCs proliferation, differentiation, and metastasis. [Read the Full Post]

A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors

283 views | Nov 16 2021

Analia Azaro et al. demonstrated that crenigacestat combined with different anticancer agents was poorly tolerated, leading to lowered dosing and disappointing clinical activity in patients with advanced or metastatic solid tumors. [Read the Full Post]

γ-secretase inhibitors, DAPT and RO4929097, promote the migration of Human Glioma Cells via Smad5-downregulated E-cadherin Expression

1174 views | Oct 01 2021

Shun-Fu Chang et al. showed that γ-secretase activity inhibition by DAPT and RO4929097 could promote LN18 and LN229 glioma cell migration via downregulating E-cadherin mRNA and protein expressions, but not via affecting E-cadherin protein processing. [Read the Full Post]

Notch inhibitors induce diarrhea, hypercrinia and secretory cell metaplasia in the human colon

605 views | Aug 30 2021

Michael Collins et al. confirmed the role of Notch signaling in intestinal homeostasis in humans. [Read the Full Post]

Incidence, predictors, and outcomes of DAPT non-compliance in planned vs. ad hoc PCI in chronic coronary syndrome

710 views | Jul 21 2021

Jahanzeb Malik et al. provided an insight on additional predictors of non-compliance to DAPT, helping us to identify and address specific patient-related factors for disruption. [Read the Full Post]

More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment

539 views | Feb 21 2021

Pilar López-Nieva et al. suggested that selective targeting γ-secretase might offer an improved efficacy and toxicity profile over the effects caused by broad-spectrum GSIs. [Read the Full Post]